<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02311764</url>
  </required_header>
  <id_info>
    <org_study_id>CTU-14005</org_study_id>
    <nct_id>NCT02311764</nct_id>
  </id_info>
  <brief_title>Carboplatin in Castration-resistant Prostate Cancer</brief_title>
  <acronym>PRO-PLAT</acronym>
  <official_title>Single Arm Open Label Phase II Pilot Study of Carboplatin in Patients With Metastatic Castrationresistant Prostate Cancer (CRPC) and PTEN Loss and/or DNA Repair Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurelius Omlin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cantonal Hospital of St. Gallen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, non-randomised phase II clinical pilot study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot Study of weekly Carboplatin in Patients with Advanced Metastatic Castration-Resistant
      Prostate Cancer (CRPC) and DNA repair defects
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>Time Frame: Up to the end of the treatment phase (ie, approximately 6 months</time_frame>
    <description>Soft tissue or PSA Response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of PSA declines of ≥30%</measure>
    <time_frame>Time Frame: At 12 weeks and up to the end of the treatment phase (ie, approximately 6 months)</time_frame>
    <description>PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Time Frame: livelong follow-up</time_frame>
    <description>Overall survival (OS) form start of Carboplatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rPFS</measure>
    <time_frame>Time Frame: Up to the end of the treatment phase (ie, approximately 6 months</time_frame>
    <description>Radiological progression-free survival (rPFS) from start of carboplatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA</measure>
    <time_frame>on studyTime Frame: Up to the end of the treatment phase (ie, approximately 6 months</time_frame>
    <description>Time to PSA progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as per CTC AEv4.03</measure>
    <time_frame>on studyTime Frame: Up to the end of the treatment phase (ie, approximately 6 months</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>On studyTime Frame: Up to the end of the treatment phase (ie, approximately 6 months</time_frame>
    <description>Disease control rate at 12 and 24 weeks (defined as SD, PR, CR, see response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTEN loss</measure>
    <time_frame>Pre-study biopsy sample</time_frame>
    <description>Evaluation of PTEN loss by FISH (Frequency and correlation with IHC)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin will be administered weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be administered weekly</description>
    <arm_group_label>Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written Informed Consent

          2. Adult patients with histological diagnosis of adenocarcinoma of the prostate.

          3. Metastatic Castration-Resistant Prostate Cancer (mCRPC)

          4. Progression after at least one taxane-based chemotherapy (or contraindication against
             taxanes) and at least one therapy with a newer hormonal agent (Cyp17 inhibitor or a
             new generation AA like enzalutamide).

          5. DNA repair defects as per central assessment

          6. Eastern Cooperative Oncology Group (ECOG) performance Status (PS) 0 - 2

          7. Progression of disease by any of the criteria listed here:

               -  PSA utilizing PCWG 2 criteria

               -  Bone scan

               -  RECIST 1.1

          8. Adequate organ and bone marrow function as evidenced by:

               -  Haemoglobin ≥8.0 g/dL

               -  Absolute neutrophil count ≥1.5 x 109/L

               -  Platelet count ≥ 100 x 109/L

               -  AST and/or ALT &lt; 2.5 x ULN, in the presence of liver metastases: AST ≥5 x ULN,
                  ALT &lt;5 x ULN

               -  Total bilirubin &lt; 2.0 x ULN (except for patients with Gilbert's disease)

               -  Creatinine Clearance ≥30ml/min

          9. Patient must agree in the biomarker studies including the fresh tumour biopsies

        Exclusion Criteria:

          1. Contraindications to the class of drugs under study, e.g. known hypersensitivity or
             allergy to class of drugs or the investigational product Carboplatin

          2. Prior treatment with any prior platinum based chemotherapy,

          3. Major surgery within 4 weeks prior to planned start of treatment

          4. Known brain or leptomeningeal involvement unless clinically stable and on stable dose
             of steroids

          5. Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc. of the participant

          6. Previous enrolment into the current study

          7. Active secondary malignancy that requires systemic therapy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurelius G Omlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital St.Gallen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurelius G Omlin, MD</last_name>
    <phone>0041714941111</phone>
    <email>aurelius.omlin@kssg.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cantonal Hospital Chur</name>
      <address>
        <city>Chur</city>
        <state>Graubuenden</state>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Cathomas, MD</last_name>
      <phone>+41 81 256 66 46</phone>
      <email>Richard.Cathomas@ksgr.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzern Cantonal Hospital</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beat Mueller, MD</last_name>
      <phone>+41412055860</phone>
      <email>beat.mueller@luks.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital St.Gallen</name>
      <address>
        <city>St.Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelius G Omlin, MD</last_name>
      <phone>0041714941111</phone>
      <email>aurelius.omlin@kssg.ch</email>
    </contact>
    <contact_backup>
      <last_name>Silke Gillessen, MD</last_name>
      <phone>0041714941111</phone>
      <email>silke.gillessen@kssg.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital of St. Gallen</investigator_affiliation>
    <investigator_full_name>Aurelius Omlin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

